Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Clinical Trials
740
Trial Phases
5 Phases
Drug Approvals
5
Clinical Trials
Distribution across different clinical trial phases (658 trials with phase data)• Click on a phase to view related trials
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2000
- Registration Number
- NCT07015905
Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT06975787
Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT06970405
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
- Conditions
- Melanoma
- Interventions
- Drug: Fianlimab+cemiplimab
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT06848088
- Locations
- 🇺🇸
Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
🇺🇸South Texas Oncology And Hematology, San Antonio, Texas, United States
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT06836609
- Locations
- 🇬🇧
Richmond Pharmacology Limited, London, Greater London, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 70
- Next
News
Hengrui and Kailera's Dual GLP-1/GIP Obesity Drug Achieves 18% Weight Loss in Phase 3 Trial
Hengrui Pharma and Kailera Therapeutics' dual-acting obesity drug HRS9531 demonstrated 18% weight loss in a Phase 3 trial in China, significantly outperforming placebo by 16%.
Health Canada Extends Evkeeza Approval to Infants as Young as 6 Months for Rare Cholesterol Disorder
Health Canada has extended approval of Evkeeza (evinacumab) to treat children as young as 6 months old with homozygous familial hypercholesterolemia (HoFH), a devastating inherited cholesterol disorder.
Regeneron and BioNTech Advance Phase 2 Trial Combining Cancer Vaccine BNT116 with Cemiplimab for Advanced NSCLC
Regeneron Pharmaceuticals and BioNTech SE are conducting a Phase 2 clinical trial evaluating the combination of investigational cancer vaccine BNT116 with cemiplimab versus cemiplimab monotherapy in advanced non-small cell lung cancer patients with PD-L1 expression ≥50%.
FDA Publishes Over 200 Drug Rejection Letters in Historic Transparency Initiative
The FDA published more than 200 Complete Response Letters (CRLs) from 2020-2024 for drug applications that were initially rejected but later approved, marking a significant step toward increased regulatory transparency.
EPO and UPC Reach Opposite Conclusions on Amgen's PCSK9 Antibody Patent Validity
The European Patent Office (EPO) Opposition Division upheld Amgen's PCSK9 antibody patent EP 3666797, finding it inventive, while the Unified Patent Court (UPC) Central Division revoked the same patent for lacking inventive step.
Sanofi Invests $25 Million in Adagene's SAFEbody Platform for Next-Generation Cancer Immunotherapy
Sanofi has committed up to $25 million in strategic investment to Adagene, extending the biotech's cash runway into 2027 and supporting clinical development of its lead SAFEbody candidate muzastotug.
Regeneron Expands Patent Protection for Aflibercept with New Formulation Patent Against Amgen
Regeneron filed a new patent infringement complaint against Amgen on June 17, 2025, asserting U.S. Patent No. 12,331,099 covering a stable liquid ophthalmic formulation without buffer requirements.
BioNTech to Acquire CureVac for $1.25 Billion to Strengthen mRNA Cancer Immunotherapy Pipeline
BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities.
Commit Biologics Forms Scientific Advisory Board to Advance Complement-Based Cancer and Autoimmune Therapies
Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform.
Regeneron's Trevogrumab Shows Promise in Preserving Muscle Mass When Combined with Wegovy in Weight-Loss Study
Regeneron's experimental drug trevogrumab, when combined with Novo Nordisk's Wegovy (semaglutide), helped preserve up to 80% of lean muscle mass compared to semaglutide alone in a mid-stage clinical study.